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Background/Aims: We present the preliminary results of a cost-effectiveness analysis of 
cyberknife radiosurgery (CKR) versus microvascular decompression (MVD) for patients with 
medically unresponsive trigeminal neuralgia.
Methods: Direct healthcare costs from hospital’s perspective attributable to CKR and MVD 
were collected. Pain level caused by trigeminal neuralgia was measured through the Barrow 
Neurological Institute pain intensity scoring criteria, at admission and after an average of 6 
months follow-up.
Results: 20 patients for both arms were enrolled, for a total of 40 patients. The two procedures 
resulted equally effective at 6 month follow-up, with different resources consumption: CKR 
reducing hospital costs by an average of 34% per patient. The robustness of these results was 
conﬁ  rmed in appropriate sensitivity analyses.
Conclusion: CKR resulted to be a cost-saving alternative compared with the surgical inter-
vention.
Keywords: decision-making, cost-effectiveness analysis, Cyberknife, microvascular decom-
pression, trigeminal neuralgia
Introduction
Technological innovation is considered as one of the principal factors of costs escala-
tion in healthcare (Oh 2005). A ﬁ  eld in which lot of technological progress has been 
registered in the last decades is radiotherapy. Radiotherapy began almost a hundred 
years ago with the discovery of X-rays and the ﬁ  rst use of the natural radioactivity. 
The greatest challenge for radiation therapy is to cure the disease while controlling 
for side-effects. Theoretically, the simplest way to achieve this with radiation is to 
encompass all target cells with sufﬁ  cient doses of radiation, while sparing surrounding 
normal tissues (Bucci et al 2005).
Nowadays the new frontier is represented by stereotactic cyberknife radio sur-
gery (CKR) that has been proven to be an effective treatment strategy for trigeminal 
neuralgia (TN) or “tic douloureux” (Lim et al 2005, 2006). Using noninvasive head 
immobilization and advanced image-guidance technology, the robotic arm of CKR 
dynamically tracks skull position and orientation during treatment, thereby ensuring 
targeting accuracy throughout the entire procedure (Romanelli et al 2005).
TN is the most common facial pain syndrome. Incidence is approximately 4.3 per 
100,000 population per year, women are more frequently affected than men: 2.5 and 
5.7 per 100,000 per year, respectively, while prevalence is approximately 15.5 per 
100,000 population per year (Wilkins 2002; Edlich et al 2006). Pain onset is usually 
in the ﬁ  fth through seventh decades of life. The disorder is characterized by unilateral, Neuropsychiatric Disease and Treatment 2008:4(3) 648
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episodic, shock-like or stabbing pain involving one or more 
divisions of the trigeminal nerve. Patient activities of daily 
living are often impaired by fear of experiencing chronic 
episodes; something as simple and routine as brushing 
the teeth, putting on make-up or even a slight breeze can 
trigger an attack, resulting in sheer agony for the patient 
(Pollok et al 2005).
Medical therapy (anticonvulsant medications, such as car-
bamazepine, phenytoin or baclofen, clonazepam, gabapentin, 
etc.) eliminates or signiﬁ  cantly reduces the pain in approxi-
mately 75% of patients, and is considered the treatment of 
choice for incident cases of TN (Fields 1996). Unfortunately, 
the relief provided by medical therapy generally decreases 
over time and is frequently resistant to multidrug regimens. 
Moreover, many patients quit medical therapy because of 
side effects, while drug intolerance is particularly common 
in elderly patients (Zakrzewska et al 2002).
Nonrespondent patients can be surgically treated 
through microvascular decompression (MVD), an invasive 
procedure that relieves the vascular compression on the 
trigeminal nerve (Burchiel et al 1988; Barker et al 1996; 
Broggi et al 2000; Sindou et al 2002; Theodosopoulos 
et al 2002). Even though MVD represents the ﬁ  rst choice 
for those patients (Fujimaki et al 1990; Lee et al 1997; 
Apfelbaum et al 2000), less invasive procedures such as 
radiofrequency rhizotomy (Taha et al 1995; Kanpolat 
et al 2001; Tronnier et al 2001), glycerol rhizotomy 
(Lundsford et al 1984; Saini 1987; Burchiel 1988; Young 
1988; North et al 1990), balloon compression (Brown et al 
1993; Skirving et al 2001) and gamma knife stereotactic 
radio surgery (Kondziolka et al 1996; Rogers et al 2000; 
Maesawa et al 2001; Pollok et al 2002; Brisman et al 2002) 
are preferred for elderly patients suffering from signiﬁ  cant 
comorbidities, or with recurrent facial pain after prior sur-
gery (Pollock et al 2005).
In all those cases, CKR is a valid alternative to surgical 
treatments for TN. However, in times of resource constraints, 
costs and beneﬁ  ts of CKR are to be evaluated against its 
closest comparator in order to provide decision makers with 
relevant information as to the impact of the new technology 
in the hospital system.
In order to perform that, a study on direct healthcare 
costs and clinical outcomes of CKR vs. MVD for TN was 
conducted, in collaboration with the Italian Diagnostic 
Centre (CDI), where a CKR system has been installed 
since July 2004, and the teaching clinic “C. Besta” National 
Neurological Institute (Besta Institute), a highly specialized 
neurological and neurosurgical centre in Milan, Italy.
The main objective of the study was to estimate the 
incremental cost-effectiveness ratio of CKR vs. MVD for 
patients non respondents to medical treatment.
Materials and methods
Study design and perspective
An observational, incidence-based cost effectiveness study 
was designed to compare CKR vs. MVD in treating medically 
unresponsive TN patients. The perspective taken was that of 
the hospital and the costs included in the analysis were direct 
healthcare costs, borne by hospital.
Patient selection
Patients were recruited in the two selected hospitals: Besta 
Institute and CDI. More speciﬁ  cally, Besta Institute was in 
charge of recruiting medically unresponsive TN patients 
treated with MVD surgery, while CDI was in charge of medi-
cally unresponsive TN patients treated by CKR.
All CKR patients were enrolled consecutively in the 
period September 2004 (when CKR was ﬁ  rst used) until June 
2005, and then followed-up for a period of 6 month. MVD 
patients were recruited retrospectively (February – August 
2004) by going through medical records. Patients were 
recruited in the study (both arms) if non respondents to 
medical treatment (Barrow National Institute Scale scores 
IV or V; see below), and were excluded if they suffered from 
a typical pain, multiple sclerosis, younger than 18, or with a 
follow-up duration of less than 6 months.
Outcome measurement
Outcome assessment referred to pain at baseline and at fol-
low-up (6 months) in the two groups of patients. Pain was 
scored level I to V according to Barrow Neurological Institute 
(BNI) pain intensity scoring criteria (Table 1) (Rogers et al 
2000). Outcome was evaluated by a standardized personal 
questionnaire administered to patients by physicians. For 
CKR patients, the questionnaire was prospectively adminis-
tered at follow-up visits. As to MVD, clinicians interviewed 
the patients by phone, after a period not inferior of 6 month 
Table 1 Barrow Neurological Institute (BNI) Pain Intensity Scoring 
Criteria
Score Description
I  No trigeminal pain
II  Occasional pain, not requiring medication
III  Some pain, adequately controlled with medication
IV  Some pain, not adequately controlled with medication
V  Severe pain/no pain reliefNeuropsychiatric Disease and Treatment 2008:4(3) 649
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from surgery. In both cases, the questionnaires were answered 
uniformly, as the same investigators scored the pain intensity 
in the two arms.
Costs evaluation
The full costing methodology was used to measure 
resource consumption, and the approach used was the 
bottom-up micro-costing. The latter is known to be the most 
rigorous approach since it requires data collection for all 
single components of care supplied by the hospital (Shuman 
et al 1992; Wolff 1998; Heerey et al 2002; Tarricone 2006). 
In the micro-costing approach, estimation of costs can be 
divided into three steps: the ﬁ  rst is to identify the health inputs 
involved in the procedure (personnel, drugs, disposables, 
equipment, length of stay, etc.), the second is to estimate the 
quantity provided, and the third step is to estimate the unit 
costs for each input.
According to the full costing approach, costs of hospital 
care were calculated summing up variable and ﬁ  xed direct 
costs exclusively associated with the operations of the wards, 
and a fair share of overheads (generally administrative and 
other central services). The latter was retrieved from the 
hospitals’ accounting department: for Besta Institute, over-
heads accounted for 18% of the direct costs, while for CDI, 
overheads accounted for 15.4%.
As for MVD, direct ﬁ  xed costs were represented by the 
usage of the operating theatre and equipment, the cost of 
labor (ie, surgical, anesthesiologist, and nursing teams), and 
the hospital stay, while variable direct costs were drugs, 
disposables, specialist visits, laboratory tests, and other 
diagnostic investigations done during hospitalization and 
follow-up.
As for CKR, direct ﬁ  xed costs referred to capital invest-
ment (CKR needs a separate bunker to be built or made 
available), equipment, and labor costs. The latter was cal-
culated on the basis of the observed time actually worked by 
each type of professional directly involved in the procedure 
(nurse, physician, radiology technician, and health physicist), 
multiplied by the cost per unit of time. Variable direct costs 
were represented by disposables, specialist visits, imaging 
tests (in particular, brain magnetic resonance imaging [MRI], 
and brain computed tomography [CT] scans), for treatment 
and follow-up.
In order to assign a monetary value to diagnostic pro-
cedures, the national fee-for-service system adopted by the 
National Health Service to fund public and private provid-
ers was used whenever full costs were not available from 
the accounting department. Drug costs for antibiotics were 
based on ofﬁ  cial ex-factory prices per unit in Italy (Agenzia 
Italiana del Farmaco 2005).
A threshold analysis was performed in order to test the 
robustness of cost differences between the two treatments.
Results
Globally, 40 patients were enrolled in the study: 20 for each 
arm. The sample characteristics are presented in Table 2.
CKR patients resulted 12 years older than MVD patients 
(p-value 0.002). Gender distribution is similar, female being 
the larger group in both the procedures (60% and 55%, 
respectively). Fewer patients in MVD group had undergone 
prior TN treatment compared with the CKR group (30% 
for MVD and 40% for CKR). The most frequent treatment 
before CKR was thermal rhizothomy (62.5%); followed by 
MVD (37.5%), whilst for MVD patients the most frequent 
procedure (67%) was another MVD.
At baseline, all patients ranked high in the BNI scale 
but CKR patients were the highest with 85% in the V class 
(p-value 0.0001).
At follow-up, 90% of patients in both groups experienced 
a reduction of severity, passing from levels V and IV to levels 
I, II, or III; while only 10% of patients in both arms did not 
experience a signiﬁ  cant pain reduction, still non respondent 
to medical treatment (Table 3). Nevertheless the difference 
was not statistically signiﬁ  cant (Chi-test p-value 0.05). 
No adverse events or major complications were registered 
Table 2 Sample size and characteristics
Procedure  CKR     MVD  
 (N  = 20)    (N = 20)
Age (at the time  Years  Years 
of the treatment)
Mean (SD)  74.2 (12.8)    61.9 (9.7) 
Range (40–88)    (41–75) 
Gender  N.  %  N.  %
Female 12  60%  11  55%
Male 8  40%  9  45%
Previous TN   N.  %  N.  %
treatment
Yes 8  40%  6  30%
No 12  60%  14  70%
Type of previous   N.  %  N.  %
TN treatment
MVD 3  38%  4  67%
Thermal rhizothomy  5  63%  1  17%
Radiosurgery –  –  1  17%
BNI Score at Baseline  N.  %  N.  %
IV. Some pain, not adequately   3  15%  15  75%
controlled with medication
V. Severe pain/no pain relief  17  85%  5  25%Neuropsychiatric Disease and Treatment 2008:4(3) 650
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in the two arms, such as toxicity. In CKR treatment group 
the number of patients recording a follow-up BNI level III is 
signiﬁ  cantly higher than in MVD group (8 cases compared 
with 2 cases), this could be explained by the fact that in CKR 
arm baseline BNI level V was also more frequent than in 
MVD arm (17 cases compared with 5 cases).
As for resources consumption, the results show that MVD 
full cost is Euro 6,641.0 (SD 1,798.8) per patient while CKR 
treatment is Euro 4,388.5 (SD 12.7) (Table 4). The difference 
of Euro 2,252.5 is mostly explained by two factors: the cost 
of the surgical procedure, which takes on average 3.5 hours 
of operating theatre, compared with 70 minutes of radiation 
for CKR, almost a standard procedure time for TN – thus 
explaining the minimum full cost variance; and the cost of 
hospital stay for MVD patients. Indeed, the length of stay is 
on average 10 days per patient (±7.4 SD); while no hospital 
stay is required for CKR patients, being it an outpatient 
service.
Notably, no drugs or laboratory tests are used speciﬁ  cally 
for CKR procedure, whilst MVD required drugs for both the 
surgical intervention and post-operation (on average 170 
doses per patient over the observation period) and laboratory 
tests (patients averaged 5 tests each). Outpatient visits per 
patient were more frequent for CKR than for MVD during 
the observation period (2.5 units vs. 1.1); on the contrary, 
imaging tests resulted less frequent in CKR compared with 
MVD (2.2 units vs. 3.1), nevertheless these were more 
expensive ones (higher frequency of CT Scans, MRIs for 
CKR vs. chest X-rays, ECGs for MVD).
A threshold analysis was performed in order to determine 
how much key baseline variables would need to change 
to equalize the resources consumption for the treatments 
(Table 5). MVD costs would break even CKR costs if the 
time of utilization of the operating theatre decreased by 
71%: 1.0 hour instead of 3.5 hours. As to the length of stay, 
CKR would still result cost saving even if MVD required no 
hospital stay at all. Conversely, CKR costs would break even 
MVD costs if the annual activity of the machine decreased 
by 46%: 155 patients per year instead of 289, or equally, 402 
fractions instead of 749.
Discussion
Technological innovation is one of the main determinants of 
healthcare costs and its rapid changes require decision makers 
to take allocative decisions in relatively short time. Economic 
evaluations are intended to support the health-related decision 
making process by informing decision makers as to allocative 
decision aimed at maximizing patients’ health by estimating 
Table 3 Clinical outcome at follow-up – BNI Scale
BNI score at baseline  CKR (N = 20)  MVD (N = 20)
  N. %  N. %
IV. Some pain, not adequately controlled with medication  3  15%  15  75%
V. Severe pain/no pain relief  17  85%  5  25%
P-value (Chi-square test)  0,0001     
BNI Score at FU  CKR (N = 20)  MVD (N = 20)
  N.  %  N.  %
I. No trigeminal pain  6  30%  9  45%
II. Occasional pain, not requiring medication  4  20%  7  35%
III. Some pain, adequately controlled with medication  8  40%  2  10%
IV. Some pain, not adequately controlled with medication  2  10%  2  10%
V. Severe pain/no pain relief  –  0%  –  0%
P-value (Chi-square test)  0,17     
Table 4 Average direct healthcare cost per patient
Full Cost  CKR    MVD    DELTA 
Cost category  Euro  %  Euro  %  Euro  %
Outpatient visits  47.4  1%  17.6  0%  −29.8  −1%
Imaging tests  437.2  10%  157.9  2%  −279.3  −12%
Radiation/Surgical procedure  3,903.9  89%  4,317.0  65%  413.1  18%
Drugs (related to procedure/TN)  –  0%  118.6  2%  118.6  5%
Laboratory tests  –  0%  73.3  1%  73.3  3%
Hospital stay costs  –  0%  1,956.7  29%  1,956.7  87%
Total  4,388.5 100% 6,641.0 100%  2,252.5 100%Neuropsychiatric Disease and Treatment 2008:4(3) 651
Effectively and efﬁ  ciently treating trigeminal neuralgia
costs and beneﬁ  ts of the new technology and comparing it 
to the prevalent clinical practice.
Stereotactic radio surgery has become an important 
treatment alternative to surgery for a variety of intracra-
nial diseases (Andrews et al 2006). In TN disease, MVD 
surgery is still considered the first line treatment for 
medical unresponsive TN (Fujimaki et al 1990; Lee et al 
1997; Apfelbaum et al 2000), nevertheless radio surgery 
cyberknife system could represent a feasible ﬁ  rst line option 
for TN in the close future, once its effectiveness has been 
robustly investigated, being it less costly than MVD, as 
emerged from this study.
Europe is experiencing a fast growth of CKR technology: 
eight CKR systems are already working in its countries at 
the time of the study, but – with the exception of the present 
study – no economic evaluation analysis has been done on 
CKR and its potential applications.
Economic evaluation analysis could be useful as to decide 
whether and how much of the technology the European 
countries can afford and for what indications it results to 
be most effective and efﬁ  cient. The present study certainly 
goes in this direction and represents an important basis for 
building further and wider evidence.
This study has some limitations. The two groups of 
patients are not directly comparable, therefore it is not 
possible to conclude that CKR is as effective as MVD. 
CKR group was signiﬁ  cantly older than the MVD group, 
even if age has not been found to be a predictor of 
success/failure for either radio surgery or MDV procedures 
(Pollock et al 2005), and patients in MVD group had typi-
cally less severe facial pain at baseline. The difference in 
patients’ characteristics is explained by the fact that CKR 
is not seen as an alternative to MVD for the time being 
but, rather, as a second line strategy whenever MVD is not 
possible to deliver.
The cost analysis does not include those associated with 
patients’ productivity losses during admission time, and 
informal care. Had these costs been evaluated, the difference 
between the two treatments would have resulted even bigger 
in favor of CKR, being an outpatient service.
Finally, more data are needed to assess the effectiveness 
of CKR considering follow-ups longer than six months 
in order to account also for recurrent trigeminal pain. The 
results obtained can be considered as preliminary, and would 
need to be further veriﬁ  ed by larger samples and longer 
follow-ups as long as the technology develops.
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